Cellprothera Sas

Cellprothera Sas company information, Employees & Contact Information

Explore related pages

Related company profiles:

CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans.

Company Details

Employees
25
Founded
-
Address
Mulhouse
Phone
33369719771
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Mulhouse
Looking for a particular Cellprothera Sas employee's phone or email?

Cellprothera Sas Questions

News

CellProthera Selects CELLforCURE by SEQENS for Phase III GMP Manufacturing - Genetic Engineering and Biotechnology News

CellProthera Selects CELLforCURE by SEQENS for Phase III GMP Manufacturing Genetic Engineering and Biotechnology News

Are We Close to a Stem Cell Therapy for Heart Failure? - Technology Networks

Are We Close to a Stem Cell Therapy for Heart Failure? Technology Networks

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing - Contract Pharma

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing Contract Pharma

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction - Diagnostic and Interventional Cardiology

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction Diagnostic and Interventional Cardiology

CellProthera inches closer to Phase III trial for heart attack cell therapy - Clinical Trials Arena

CellProthera inches closer to Phase III trial for heart attack cell therapy Clinical Trials Arena

Cell and gene therapy development moves into cardiac indications - Drug Target Review

Cell and gene therapy development moves into cardiac indications Drug Target Review

CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction - Drug Discovery News

CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction Drug Discovery News

Cell therapy could help curb progression of heart failure - European Pharmaceutical Review

Cell therapy could help curb progression of heart failure European Pharmaceutical Review

Cell therapy weekly: Reversing alopecia by reawakening dormant stem cells - RegMedNet

Cell therapy weekly: Reversing alopecia by reawakening dormant stem cells RegMedNet

Regulatory and logistics concerns prompt Cellprothera to keep cell therapy trial in-house - BioXconomy

Regulatory and logistics concerns prompt Cellprothera to keep cell therapy trial in-house BioXconomy

Evaluation of expanded peripheral blood derived CD34+ cells for the treatment of moderate knee osteoarthritis - Frontiers

Evaluation of expanded peripheral blood derived CD34+ cells for the treatment of moderate knee osteoarthritis Frontiers

CD34+ cells for cell and gene therapy development: an interview with Dr Manon Destalminil - RegMedNet

CD34+ cells for cell and gene therapy development: an interview with Dr Manon Destalminil RegMedNet

Top Cellprothera Sas Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant